Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ustekinumab
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Bio-Thera Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
EC Approves Bio-Thera’s Stelara Biosimilar USYMRO
Details : Usymro (ustekinumab) is a human IL-12 and IL-23 antagonist indicated for the treatment of adult patients with moderate to severe Crohn’s disease.
Product Name : Usymro
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 26, 2025
Lead Product(s) : Ustekinumab
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Bio-Thera Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Azilsartan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Azilsartan 80mg Vs Edarbi 80mg Bioequivalence Study
Details : Azilsartan is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Hypertension.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 25, 2025
Lead Product(s) : Azilsartan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Empagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 12, 2025
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Empagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2025
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Empagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : Empagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Collaboration
AbbVie, Gedeon Richter Partner on Neuropsychiatric Drug Discovery
Details : Companies will discover and develop novel targets for the treatment of neuropsychiatric conditions. AbbVie will have worldwide commercialization rights except for traditional markets of Richter.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $25.0 million
October 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives approval from EU in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Product Name : Ryeqo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 02, 2023
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Sumitomo
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ryeqo (relugolix, estradiol, and norethisterone acetate) receives positive opinion by CHMP recommending approval in for the adjuvant treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.
Product Name : Ryeqo
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 15, 2023
Lead Product(s) : Relugolix,Estradiol,Norethisterone Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Sumitomo
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-932
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABBV-932 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anxiety Disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : ABBV-932
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Recipient : AbbVie Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RGH-706
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
Details : RGH-706 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prader-Willi Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 11, 2022
Lead Product(s) : RGH-706
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable